These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29055016)

  • 1. SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.
    Orlacchio A; Ranieri M; Brave M; Arciuch VA; Forde T; De Martino D; Anderson KE; Hawkins P; Di Cristofano A
    Cancer Res; 2017 Dec; 77(24):6914-6926. PubMed ID: 29055016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
    Maurer M; Su T; Saal LH; Koujak S; Hopkins BD; Barkley CR; Wu J; Nandula S; Dutta B; Xie Y; Chin YR; Kim DI; Ferris JS; Gruvberger-Saal SK; Laakso M; Wang X; Memeo L; Rojtman A; Matos T; Yu JS; Cordon-Cardo C; Isola J; Terry MB; Toker A; Mills GB; Zhao JJ; Murty VV; Hibshoosh H; Parsons R
    Cancer Res; 2009 Aug; 69(15):6299-306. PubMed ID: 19602588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D; Hou P; Liu Z; Wu G; Xing M
    Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGK1: The Dark Side of PI3K Signaling.
    Di Cristofano A
    Curr Top Dev Biol; 2017; 123():49-71. PubMed ID: 28236975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
    Guo JP; Coppola D; Cheng JQ
    J Biol Chem; 2011 Oct; 286(43):37389-98. PubMed ID: 21908616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR.
    Gonçalves AP; Videira A; Soares P; Máximo V
    Life Sci; 2011 Sep; 89(11-12):371-7. PubMed ID: 21807000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.
    Gu Z; Wang L; Yao X; Long Q; Lee K; Li J; Yue D; Yang S; Liu Y; Li N; Li Y
    Cell Death Dis; 2020 Oct; 11(10):898. PubMed ID: 33093458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
    Kunnimalaiyaan M; Ndiaye M; Chen H
    Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma.
    Uddin S; Bavi P; Siraj AK; Ahmed M; Al-Rasheed M; Hussain AR; Ahmed M; Amin T; Alzahrani A; Al-Dayel F; Abubaker J; Bu R; Al-Kuraya KS
    Endocr Relat Cancer; 2010 Mar; 17(1):191-202. PubMed ID: 20008098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.
    Read RD; Fenton TR; Gomez GG; Wykosky J; Vandenberg SR; Babic I; Iwanami A; Yang H; Cavenee WK; Mischel PS; Furnari FB; Thomas JB
    PLoS Genet; 2013; 9(2):e1003253. PubMed ID: 23459592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of Long Non-coding RNA ENST00000606790.1 Inhibits the Malignant Behaviors of Papillary Thyroid Carcinoma through the PI3K/AKT Pathway.
    Zuo Z; Liu L; Song B; Tan J; Ding D; Lu Y
    Endocr Res; 2021 Feb; 46(1):1-9. PubMed ID: 32791924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
    Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
    Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
    Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
    Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.
    Du L; Chen X; Cao Y; Lu L; Zhang F; Bornstein S; Li Y; Owens P; Malkoski S; Said S; Jin F; Kulesz-Martin M; Gross N; Wang XJ; Lu SL
    Oncogene; 2016 Sep; 35(35):4641-52. PubMed ID: 26876212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
    Liu R; Liu D; Trink E; Bojdani E; Ning G; Xing M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E577-85. PubMed ID: 21289267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.
    Miller KA; Yeager N; Baker K; Liao XH; Refetoff S; Di Cristofano A
    Cancer Res; 2009 Apr; 69(8):3689-94. PubMed ID: 19351816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
    Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N
    J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant.
    Li T; Wang J; Wang X; Yang N; Chen SM; Tong LJ; Yang CH; Meng LH; Ding J
    J Pharmacol Exp Ther; 2010 Sep; 334(3):830-8. PubMed ID: 20522531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.